恩华药业：NH600001乳状注射液临床试验研究受试者已全部出组，目前正在进行数据统计工作

Core Viewpoint - The company Enhua Pharmaceutical (002262.SZ) has made progress in the registration application for its raw material drug NH600001, which was accepted on July 29, 2025 [2] Group 1: Company Updates - The NDA (New Drug Application) for NH600001 has been submitted and is currently under review [2] - All subjects have completed the clinical trial for NH600001 emulsion injection, and data analysis is ongoing [2] - The company plans to submit the market registration application after completing the clinical summary report [2]